Lantheus Holdings (NASDAQ: LNTH) reported Q1 EPS of $0.05, $0.06 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $92.51 million versus the consensus estimate of $87.24 million.

• Worldwide revenue of $92.5 million for the first quarter 2021, representing an increase of 2.0% from the prior year period
• Net income of $9.0 million for the first quarter 2021, compared to net income of $3.3 million in the prior year period
• GAAP fully diluted EPS of $0.13 for the first quarter 2021, compared to GAAP fully diluted EPS of $0.08 in the prior year period; adjusted fully diluted EPS of $0.05 for the first quarter 2021, compared to adjusted fully diluted EPS of $0.36 in the prior year period
• Net cash provided by operating activities was $9.8 million for the first quarter 2021. Free cash flow was $7.3 million in the first quarter 2021
• The Company provides second quarter 2021 revenue and adjusted diluted earnings per share guidance; updates full year guidance

“We had a strong start to 2021 with solid first quarter revenue and earnings overperformance driven mainly by DEFINITY volume. While COVID-19 did impact the early part of the quarter, we are encouraged by the continued trend toward in-person delivery of healthcare,” said Mary Anne Heino, President and CEO. “Currently, we are focused on preparation for the potential FDA approval and commercial launch of PyL, a best-in-class PSMA prostate cancer imaging agent, to help drive long-term value for patients, healthcare professionals, and shareholders.”

GUIDANCE:

Lantheus Holdings sees Q2 2021 EPS of $0.03-$0.05, versus the consensus of $0.04. Lantheus Holdings sees Q2 2021 revenue of $93-97 million, versus the consensus of $93.25 million.

Lantheus Holdings sees FY2021 EPS of $0.36-$0.41, versus the consensus of $0.37. Lantheus Holdings sees FY2021 revenue of $390-400 million, versus the consensus of $390.55 million.

For earnings history and earnings-related data on Lantheus Holdings (LNTH) click here.